WATERTOWN, Mass. — Sai Life Sciences hosted its Biotech Pitch Day 2026 at its site here, drawing emerging innovators, scientific leaders, and industry experts from across the U.S., Europe, and India.
The event provided a platform for early-stage biotech companies to showcase their science, enhance visibility, and engage with potential collaborators across the drug discovery ecosystem. Participating start-ups represented a diverse range of scientific approaches and perspectives, reflecting the breadth of innovation shaping the future of biotechnology.
As part of the initiative, selected start-ups gained the opportunity to collaborate with Sai Life Sciences, leveraging its integrated drug discovery capabilities, scientific expertise, and advanced infrastructure to help accelerate their programs. Ten promising companies were invited to present following a competitive selection process, engaging in meaningful discussions with peers, mentors, and a distinguished panel of judges.
“Biotech Pitch Day 2026 reflects our commitment to engaging more closely with the global innovation ecosystem,” said Maneesh Pingle, Executive Vice President and Head of Discovery Services at Sai Life Sciences. “We were encouraged by the quality of science and the diversity of ideas presented, and by the openness with which founders engaged in dialogue. Beyond identifying promising programs, the event was about building connections — and we see this as the beginning of several meaningful collaborations.”
Finalist Cohort
The finalist cohort included Zena Therapeutics Inc., Luciole Pharmaceuticals, Inc., NuCyRNA Therapeutics, Myracle Therapeutics, AudazBio, Inc., Block Biosciences, Weld Pharmaceuticals, Cryptyx Bioscience, VISTARA BIOSCIENCE, and Neuropathix, Inc.
Recognizing Standout Innovators
Following a full day of presentations and discussions, three companies were recognized for their exceptional scientific rigor and compelling vision:
- Block Biosciences
- Neuropathix, Inc.
- Zena Therapeutics Inc.
Special recognition was also extended to Cryptyx Bioscience and Tag Team Therapeutics for their strong and thoughtful pitches.
Expert Evaluation and Industry Engagement
Presentations were evaluated by panel of distinguished healthcare experts who served as judges, including Daniel Resnicow, Operating Partner at Engine Ventures, Stephanos Ioannidis, Leader of the Modalities Innovation Lab at Astellas Pharma, Bharat Lagu, an independent R&D executive, and Arjun Goyal, Founder and Managing Partner of Vianti Capital, LLC. Their insights and feedback contributed to a highly engaging and enriching experience for all participants.
Driving Future Partnerships
The event builds on Sai Life Sciences’ broader commitment to supporting biotech startups through access to scientific expertise, infrastructure, and collaborative opportunities. Participants gained deeper visibility into the company’s integrated drug discovery platform and explored potential pathways for partnership.
With strong participation, high-quality science, and vibrant discussions, Biotech Pitch Day 2026 underscored the growing importance of collaborative platforms in accelerating innovation. Sai Life Sciences looks forward to continuing these conversations and building meaningful partnerships with the global biotech community
